远程医疗公司Hims & Hers Health Inc (HIMS)今日盘中股价大跌5.08%，引发市场关注。这一跌幅主要源于制药巨头与白宫就减肥药价格达成的新协议。
据报道，美国总统特朗普与制药公司诺和诺德和礼来制药达成协议，将大幅降低GLP-1类减肥药物的价格。根据协议，这些药物的平均月服用价格将降至149美元至350美元之间，远低于当前市场价格。这一举措旨在扩大药物的使用范围，使更多美国人能够负担得起这些备受关注的减肥药。
分析人士指出，这一协议可能对Hims & Hers等远程医疗公司产生显著影响。作为一家提供多种健康和保健服务的平台，Hims & Hers也涉足减肥市场。随着主流减肥药价格的大幅下降，公司可能面临更激烈的市场竞争，这可能导致其在减肥领域的业务受到挑战。投资者担忧这可能影响公司未来的盈利能力，从而引发了今日的股价下跌。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.